Institutional Ownership
Black Diamond Therapeutics I
CUSIP 09203E105COMBDTXQ1 2026
13D / 13G Filings
33
Schedule 13D/13G on record
Beneficial Filers
12
Distinct reporting persons
Largest Stake
19.0%
Max % of class reported
Institutional Holders
103
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
33 filings · latest Feb 17, 2026
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Feb 17, 2026 | Vestal Point Capital, LP | 13G/A | 1.5% | 870.0K | SEC |
| 2 | Apr 29, 2025 | Blackrock, Inc. | 13G/A | 4.5% | 2.52M | SEC |
| 3 | Mar 21, 2025 | Bb Biotech AG | 13G/A | 4.8% | 2.73M | SEC |
| 4 | Feb 14, 2025 | Bb Biotech AG | 13G/A | 15.1% | 8.52M | SEC |
| 5 | Nov 14, 2024 | T. Rowe Price Investment Management, Inc. | 13G/A | 19.0% | 10.73M | SEC |
| 6 | Nov 14, 2024 | Vestal Point Capital, LP | 13G | 8.9% | 5.03M | SEC |
| 7 | Nov 8, 2024 | Blackrock, Inc. | 13G | 6.2% | 3.50M | SEC |
| 8 | Oct 24, 2024 | Blackrock, Inc. | 13G | 6.2% | 3.50M | SEC |
| 9 | Aug 8, 2024 | Versant Venture Capital Vi, L.P. | 13D/A | 7.0% | 3.95M | SEC |
| 10 | Jul 10, 2024 | T. Rowe Price Investment Management, Inc. | 13G/A | 18.9% | 10.66M | SEC |
23 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for Black Diamond Therapeutics I.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Nea Management Company, LLC | 4.45M | $9.48M |
| 2 | Vanguard Capital Management LLC | 1.85M | $3.94M |
| 3 | Renaissance Technologies LLC | 1.64M | $3.50M |
| 4 | Dimensional Fund Advisors LP | 1.30M | $2.77M |
| 5 | Blackrock, Inc. | 1.11M | $2.36M |
| 6 | Connor, Clark & Lunn Investment Management Ltd. | 1.06M | $2.25M |
| 7 | Mackenzie Financial Corp | 844.8K | $1.80M |
| 8 | Marshall Wace, LLP | 836.3K | $1.78M |
| 9 | Arrowstreet Capital, Limited Partnership | 834.6K | $1.78M |
| 10 | Bridgeway Capital Management, LLC | 723.5K | $1.54M |